sch 34826 has been researched along with sch 32615 in 1 studies
| Studies (sch 34826) | Trials (sch 34826) | Recent Studies (post-2010) (sch 34826) | Studies (sch 32615) | Trials (sch 32615) | Recent Studies (post-2010) (sch 32615) |
|---|---|---|---|---|---|
| 31 | 2 | 0 | 32 | 2 | 0 |
| Protein | Taxonomy | sch 34826 (IC50) | sch 32615 (IC50) |
|---|---|---|---|
| Neprilysin | Oryctolagus cuniculus (rabbit) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sybertz, EJ | 1 |
1 review(s) available for sch 34826 and sch 32615
| Article | Year |
|---|---|
SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Dioxolanes; Dipeptides; Drug Synergism; Heart Failure; Humans; Hypertension; Neprilysin; Prodrugs; Rats | 1991 |